メリーランド州における乳がんの臨床試験
メリーランド州内の拠点で、乳がんに関する68件の研究が参加者を募集しています。
メリーランド州内の都市
公式研究テキスト（英語）
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Mercy Medical Center, Baltimore
- Maryland Oncology Hematology P A, Silver Spring
被験者募集中第3相
18歳〜100歳 · 全性別 · 2026/10/02更新 · NCT05827081Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Medical Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore
- 他10件
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
- National Institutes of Health Clinical Center, Bethesda
被験者募集中観察研究
3歳以上 · 全性別 · 2026/10/02更新 · NCT01441089Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
- National Institutes of Health Clinical Center, Bethesda
被験者募集中第2相
18歳〜72歳 · 全性別 · 2026/10/02更新 · NCT01174121Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases
- National Institutes of Health Clinical Center, Bethesda
被験者募集中観察研究
18歳〜120歳 · 全性別 · 2026/10/02更新 · NCT07619534A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Johns Hopkins University, Baltimore
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06172478A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
- Maryland Oncology Hematology, Laurel
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07102381Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy
- Maryland Proton Treatment Center, Baltimore
被験者募集中第3相
19歳以上 · 女性 · 2026/09/29更新 · NCT05856773Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
- Maryland Proton Treatment Center, Baltimore
被験者募集中第2相
50歳以上 · 女性 · 2026/09/29更新 · NCT01766297Collection of Blood From Patients With Cancer
- National Institutes of Health Clinical Center, Bethesda
被験者募集中観察研究健康なボランティア歓迎
18歳以上 · 全性別 · 2026/09/28更新 · NCT00034216Genomic Services Research Program
- National Institutes of Health Clinical Center, Bethesda
被験者募集中観察研究
1 Month – 105 Years · 全性別 · 2026/09/28更新 · NCT02595957Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
- National Institutes of Health Clinical Center, Bethesda
被験者募集中第2相
18歳〜72歳 · 全性別 · 2026/09/28更新 · NCT03412877A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Mercy Medical Center - Baltimore ( Site 0015), Baltimore
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06966700A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Greenebaum Comprehensive Cancer Center ( Site 0036), Baltimore
- Holy Cross Hospital ( Site 0073), Silver Spring
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06312176A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Columbia
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06103864Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Clinical Trial Site, Annapolis
- Clinical Trial Site, Baltimore
- Clinical Trial Site, Baltimore
- 他1件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/23更新 · NCT07085767A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- American Oncology Partners, PA, Bethesda
- James M Stockman Cancer Institute, Frederick
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07174336A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- United Theranostics, Glen Burnie
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07213791A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
- Medstar Research Institute, Hyattsville
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/21更新 · NCT05894239Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/18更新 · NCT07340541ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- Saint Agnes Hospital, Clinical Research Center, Baltimore
- Maryland Oncology Hematology P.A., Columbia
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/17更新 · NCT07173751A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Mercy Medical Center, Baltimore
- Ascension St. Agnes Hospital, Baltimore
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
- 他1件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/15更新 · NCT06492616A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, Baltimore
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/11更新 · NCT05123482A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
- Maryland Oncology Hematology - Annapolis, Annapolis
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/08更新 · NCT07100106Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins, Baltimore
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/03更新 · NCT06982521Cardiometabolic Screening Program
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
被験者募集中
18歳以上 · 全性別 · 2026/09/03更新 · NCT05386719PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
被験者募集中第2相
18歳以上 · 女性 · 2026/09/03更新 · NCT06245889A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Velocity Clinical Research, Annapolis
- University of Maryland, Baltimore
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/03更新 · NCT06790693The Vanguard Study: Testing a New Way to Screen for Cancer
- Walter Reed National Military Medical Center, Bethesda
被験者募集中健康なボランティア歓迎
45歳〜75歳 · 全性別 · 2026/09/02更新 · NCT06995898Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Mercy Medical Center, Baltimore
- Greater Baltimore Medical Center, Baltimore
- 他17件
被験者募集中第3相
18歳〜60歳 · 女性 · 2026/09/02更新 · NCT05879926Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- The Center for Cancer and Blood Disorders a division of American Oncology Partners, P.A., Bethesda
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/02更新 · NCT06072612A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
- The Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine, Baltimore
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/21更新 · NCT06764940A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)
- National Institutes of Health Clinical Center, Bethesda
被験者募集中
18歳〜120歳 · 全性別 · 2026/08/21更新 · NCT07067138Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/17更新 · NCT06500481Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
- National Institutes of Health Clinical Center, Bethesda
被験者募集中第1/2相
18歳〜72歳 · 全性別 · 2026/08/13更新 · NCT02830724A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Local Institution - 1035, Baltimore
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/08/10更新 · NCT06926868Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery
- Walter Reed National Military Medical Center, Bethesda
被験者募集中
18歳以上 · 全性別 · 2026/08/07更新 · NCT07140172Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
- Maryland Oncology Hematology, Annapolis
被験者募集中第3相
18歳〜100歳 · 全性別 · 2026/08/06更新 · NCT05232916Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Maryland Oncology Hematology, Rockville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/04更新 · NCT05579366E-Mindfulness Approaches for Living After Breast Cancer
- Maryland Proton Treatment Center, Baltimore
- University of Maryland/Greenebaum Cancer Center, Baltimore
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore
- 他14件
被験者募集中第3相
18歳〜50歳 · 全性別 · 2026/08/04更新 · NCT06748222ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。